摘要
目的探讨视黄醇受体(RAR)β基因的DNA甲基化在乳腺癌发生发展过程中的意义。方法采用特异性MSP方法,检测乳腺癌和正常乳腺组织中RARβ基因的DNA甲基化状态,并结合其临床病理特性和预后进行分析。结果 192例乳腺癌组织中RARβ基因甲基化者50例(26%),而在正常乳腺组织中无一例甲基化,甲基化率与患者的肿瘤组织学类型、分期和肿瘤大小有相关性(P<0.05);淋巴结转移、ER阴性及HER2过度表达的癌组织中RARβ基因甲基化率增高,但无统计学意义。RARβ基因甲基化的乳腺癌患者的生存率低(P=0.268),尤其是淋巴结转移的乳腺癌患者(P=0.040)。结论 RARβ基因甲基化在乳腺癌的发生、发展中起着重要作用,可能与乳腺癌的侵袭性密切相关,可作为判断淋巴结转移的乳腺癌预后的分子生物学指标。
Objective To determine the roles of retionoic acid receptor β(RARβ) gene methylation in the occurrence and development of breast cancer. Methods We screened the primary human breast tumors and normal breast tissues for RARβ gene promoter methylation by methylation specify PCR(MSP), and the results were analyzed together with corresponding clinical pathological data. Results The frequency of RARβ gene methylation in 192 cases was 26%(50/192), however no RARβ gene methylation was found in normal breast tissues. RARβ methylation were associated with tumor histological type, staging and tumor size(P<0.05). Patients with lymph node metastasis, ER(-)and HER2 amplified had more RARβmethylation(P>0.05). Patients with RARβ methylation had low survival rate(P=0.268), particularly those combined with lymphatic metastasis(P=0.04). Conclusion RARβ gene promoter methylation may play an important role in the carcinogenesis and development of breast cancer. The relationship with poor differentiation, large tumor size and poor survival rate indicates that RARβ methylation could be used in the prognosis of breast cancer patients with lymphatic metastasis.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2014年第5期443-446,共4页
Cancer Research on Prevention and Treatment
